This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exact Sciences, Vericel Corp, Home Depot, ExxonMobil and Discover Financial Services highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Exact Sciences, Vericel Corp, Home Depot, ExxonMobil and Discover Financial Services highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Exact Sciences (EXAS)
by Kevin Cook
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
by Zacks Equity Research
Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.
If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic (HOLX) ThinPrep Genesis Processor Gets FDA Approval
by Zacks Equity Research
Hologic's (HOLX) ThinPrep Genesis processor offers new automation capabilities and workflow enhancements.
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.
Exact Sciences (EXAS) Reveals Promising Data on Cologuard
by Zacks Equity Research
Modeling data exhibits efficacy of Exact Sciences' (EXAS) Cologuard compared to FIT and other colorectal cancer diagnostic options.
Strength Seen in Exact Sciences (EXAS): Can Its 9.2% Jump Turn into More Strength?
by Zacks Equity Research
Exact Sciences (EXAS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks Market Edge Highlights: Shopify, PayPal, DraftKings, Exact Sciences and Tesla
by Zacks Equity Research
Zacks Market Edge Highlights: Shopify, PayPal, DraftKings, Exact Sciences and Tesla
Are You a Glass Half Full or Half Empty Investor?
by Tracey Ryniec
Buying the stock market weakness? Or staying on the sidelines? Your outlook may determine your investing strategy during corrections.
Exact Sciences (EXAS) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2021 revenues improved year over year led by growth in Precision Oncology, COVID-19 testing and Screening revenues.
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 82.69% and 4.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Bear of the Day: Guardant Health (GH)
by Kevin Cook
Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise
Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement
by Zacks Equity Research
Myriad Genetics' (MYGN) myChoice test's additional reimbursement will now make it available for use in first-line treatment of advanced ovarian cancer patients.
Software is the New Gold: Storing Value in the Digital-Crypto Age
by Kevin Cook
Time for the final nail in the gilded sarcophagus of the barbarous relic.
Why Is Exact Sciences (EXAS) Down 8.9% Since Last Earnings Report?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for March 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Exact Sciences (EXAS) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.
Is a Surprise Coming for Exact Sciences (EXAS) This Earnings Season?
by Zacks Equity Research
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales. However, coronavirus-led disruption is likely to have hurt sales.
Exact Sciences (EXAS) Posts Solid Preliminary Q4 Testing Revenues
by Zacks Equity Research
Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.